Actavis

Sindan to rebrand as Actavis

Published in Cancer Weekly, May 15th, 2007

Sindan, the leading European generic pharmaceutical company specializing in the manufacturing and distribution of oncology products, will be rebranded as Actavis with immediate effect. This follows Actavis' acquisition of Sindan in March 2006 and the completed integration of the business.

Since its acquisition by Actavis, Sindan has continued to experience strong growth. The business generated revenues of EUR95 million in 2006 and expectations for 2007 are for sales of EUR115 million.

Additional investment expected to build platform for future growth

Actavis is committed to extending its business in Romania and its capabilities...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2007-05-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry